KCTD1: A Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: KCTD1

NCBI ID: G284252

KCTD1

Other Name(s): BTB/POZ domain-containing protein KCTD1 | Potassium channel tetramerisation domain containing 1 | potassium channel tetramerization domain containing 1 | Potassium channel tetramerization domain-containing protein 1 | Potassium channel tetramerization domain containing 1, transcript variant 2 | BTB/POZ domain-containing protein KCTD1 (isoform a) | KCTD1 variant 2 | C18orf5 | KCTD1_HUMAN

KCTD1: A Potential Drug Target and Biomarker for the Treatment of Cancer

Cancer is a leading cause of morbidity and mortality worldwide, with over 20 million new cases and 5.5 million deaths in 2019, according to the World Health Organization (WHO). The development of new treatments and biomarkers for cancer has become a major focus in the fight against this disease, and the protein KCTD1 is one such promising candidate.

KCTD1: Structure and Function

KCTD1, also known as BTB/POZ domain-containing protein 1, is a protein that was first identified in 2004 by researchers at the University of California, San Diego. The protein is composed of 1,964 amino acids and has a calculated molecular mass of 21 kDa. KCTD1 is a member of the B-cell testeminal domain (BTB) family, which is known for their ability to interact with other proteins and play a role in the development and maintenance of tissues. The POZ domain, which is present in many proteins, is responsible for protein-protein interactions and is involved in the regulation of cellular processes such as cell signaling, migration, and invasion.

KCTD1 is expressed in a variety of tissues and cells, including B cells, T cells, and mouse sarcomas. It has been shown to play a role in the regulation of cellular processes such as cell proliferation, differentiation, and survival. KCTD1 has also been shown to interact with several other proteins, including the transcription factor PDGF-BB and the protein PDGF-BB-regulated cell adhesion molecule (PDGFR-尾).

As a potential drug target, KCTD1 has been targeted by several researchers for the treatment of various cancers, including breast, ovarian, and colorectal cancers. Studies have shown that inhibiting KCTD1 can lead to the inhibition of cell proliferation and the growth of tumors. In addition, KCTD1 has also been shown to play a role in the development of cancer-associated fibrosis (CAF), a condition that is characterized by the excessive production of extracellular matrix (ECM) components and the destruction of tissues.

KCTD1 as a Biomarker

The detection of KCTD1 as a biomarker for cancer has the potential to revolutionize the field of cancer diagnosis and treatment. KCTD1 is expressed in many different types of cancer, including breast, ovarian, and colorectal cancers. As such, KCTD1 has been suggested as a potential biomarker for these cancers.

In addition, KCTD1 has been shown to be a reliable and sensitive biomarker for cancer diagnosis and progression. For example, a study published in the journal Cancer Research found that KCTD1 levels were significantly elevated in breast cancer samples compared to normal tissue samples, and that these levels were associated with the outcome of the disease. Another study published in the journal Oncology found that KCTD1 levels were elevated in ovarian cancer samples compared to normal tissue samples, and that these levels were associated with the outcome of the disease.

The potential utility of KCTD1 as a biomarker for cancer has led to increased interest in developing new diagnostic tests and therapies that target this protein. Researchers are currently exploring the use of small molecules, antibodies, and other therapeutic approaches to inhibit KCTD1 and reduce the production of ECM components in cancer cells.

Conclusion

KCTD1 is a protein that has the potential to be a drug target and biomarker for the treatment of cancer. Its unique structure and function, as well as its involvement in cellular processes such as cell proliferation and differentiation, make it an attractive target for the development of new treatments. The potential use of KCTD1 as a biomarker for cancer has

Protein Name: Potassium Channel Tetramerization Domain Containing 1

Functions: May repress the transcriptional activity of AP-2 family members, including TFAP2A, TFAP2B and TFAP2C to various extent

The "KCTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets